Antonino Amato was born in Padova (Italy) on September 24, 1958. He got a degree in Medicine in 1983 at the School of Medicine of the Università Cattolica del Sacro Cuore in Rome, Italy and attended a residency program in General Surgery at the Tor Vergata University School of Medicine up to 1988.
Since July 1st, 2018 he is the CEO of BetaGlue Technologies SpA, an oncologic start-up focusing on the treatment of solid tumors using an internal radiotherapy platform which uses the controlled release of energy by 90Yttrium. BetaGlue is funded by two Italian venture capital groups (Panakes and Innogest), which are very active in the med-tech area in Italy, Europe, Israel and the USA.
He has been the founder and Executive Director of the Clinical Trial Center of Fondazione Policlinico Universitario A. Gemelli (Rome) since January 2013, a department which was then spun-off as an independent company named CTC SpA in 2017 and for which he served as Managing Director.
He has a 30-yr. experience in drug development worldwide, both in the USA and in Europe. In fact, from 1996 to 2006, dr. Amato was appointed first as Medical Director, and then as General Manager and Chief Operating Officer of Sigma-Tau Research Inc., an R&D company belonging to the Sigma Tau group and located in the United States. Such an appointment followed his entry into Sigma Tau Italy in 1991 as an Associate Director of Clinical Research in the International Clinical Research Department of the Pomezia (Rome) site.
Dr. Amato came back to Italy in 2006 and was appointed Corporate Director, Product Development at the global level for Sigma Tau, a position held until Dec 2012.
Dr. Amato was a member of the Italian Society of Surgery, Italian Society of Colo-proctology, International Society of Vascular Medicine and Biology, International Union of Angiology, American Society of Clinical Oncology and Drug Information Association. He has published more than 100 peer-reviewed papers, appearing on the American Journal of Medicine, Diabetes, the Journal of Kidney Disease, the European Journal of Cancer, the Journal of Vascular Surgery and on Vascular Medicine.
He has been a non-executive member of the board of Sigma-Tau Research from January 2007 to December 2010, and an executive member of the board of Molipharma, an R&D spin-off company of the Catholic University School of Medicine since January 2014. He has been appointed President of the Scientific Advisory Board of Therametrics since July 2014 and, from May 2016 to Jan 2017, he has been a board member of Relief Therapeutics, a Swiss stock market-listed company, into which Therametrics has merged.